Author:
Jakubowiak Andrzej,Usmani Saad Z.,Krishnan Amrita,Lonial Sagar,Comenzo Raymond L.,Wang Jianping,de Boer Carla,Deraedt William,Weiss Brendan M.,Schecter Jordan M.,Chari Ajai
Funder
Janssen Pharmaceuticals
Janssen Research and Development
Takeda Pharmaceuticals U.S.A.
Subject
Cancer Research,Oncology,Hematology
Reference60 articles.
1. Clinical treatment of newly diagnosed multiple myeloma;Cejalvo;Expert Rev Hematol,2015
2. Relapsed or relapsed/refractory multiple myeloma;Kurtin;J Adv Pract Oncol,2013
3. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial;Durie;Lancet,2017
4. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma;Attal;N Engl J Med,2017
5. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献